

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04422 A2

(51) International Patent Classification⁷: **C07D 217/00**

(21) International Application Number: PCT/US01/16491

(22)-International Filing Date: 25 June 2001 (25.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/217,556 12 July 2000 (12.07.2000) US

(71) Applicant (*for all designated States except US*): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta, Kalamazoo, MI 49001 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): SCHNUTE, Mark, E. [US/US]; 4459 Wimbledon Way, Kalamazoo, MI 49009 (US).

(74) Agent: YANY, Lucy, X.; Intellectual Property Legal Services, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS



(I)

(57) Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents viruses of the herpes family.

WO 02/04422 A2

HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS

Background of the Invention

5 1. Field of the Invention

The present invention provides heterocycle carboxamide derivatives. These compounds are useful as antiviral agents, in particular, as agents against viruses of the herpes family.

10

2. Technology Description

The herpesviruses comprise a large family of double stranded DNA viruses. They are also a source of the most common viral illnesses in man. Eight of the herpes viruses, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV),
15 human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and human herpes viruses 6, 7, and 8 (HHV-6, HHV-7, and HHV-8), have been shown to infect humans.

HSV-1 and HSV-2 cause herpetic lesions on the lips and genitals, respectively. They
20 also occasionally cause infections of the eye and encephalitis. HCMV causes birth defects in infants and a variety of diseases in immunocompromised patients such as retinitis, pneumonia, and gastrointestinal disease. VZV is the causative agent of chicken pox and shingles. EBV causes infectious mononucleosis. It can also cause lymphomas in immunocompromised patients and has been associated with Burkitt's
25 lymphoma, nasopharyngeal carcinoma, and Hodgkins disease. HHV-6 is the causative agent of roseola and may be associated with multiple sclerosis and chronic fatigue syndrome. HHV-7 disease association is unclear, but it may be involved in some cases of roseola. HHV-8 has been associated with Kaposi's sarcoma, body cavity based lymphomas, and multiple myeloma.

30

U.S. Patent Nos. 5,753,666 and 5,891,878 and WO 97/04775 disclose specific 1-alkyl-substituted-quinolone-3-carboxamides that are alleged to have therapeutic utility via inhibition of Phosphodiesterase IV esterase and/or Tumor Necrosis factor activity.

Commonly assigned WO 00/40561 discloses quinolinecarboxamides as antiviral agents.

- 5 Commonly assigned WO 00/40563 discloses specific quinolinecarboxamides as antiviral agents.

Commonly assigned WO 00/53610 discloses 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents.

10

Commonly assigned WO99/32450 discloses specific 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents.

- U.S. Patent No. 5,945,431 discloses specific naphthyridine heterocyclic compounds
15 having antiviral activity that are useful in the therapy and prophylaxis of cytomegalovirus (CMV) infection in mammals.

- WO99/10347 discloses specific substituted 4-oxo-naphthyridine-3-carboxamides as brain receptor ligands having potential use in the treatment of central nervous system
20 diseases and/or disorders.

WO98/19673 discloses specific heterocyclic agents for the treatment of diseases caused by viruses.

- 25 JP08301849 discloses specific heterocyclic agents useful as tachykinin receptor antagonists. They are suggested for use in treatment of the following diseases: inflammation, allergic diseases, CNS disorders, digestive system disorders, urinary tract disorders, cardiovascular diseases immunopathy. The reference suggests that the inventive compounds can be used to treat herpes, but classifies herpes as either an
30 inflammation or allergic reaction disease. The reference does not suggest that the compounds can be used to treat infectious diseases.

JP07033729 discloses specific N-cyano-N'-substituted-arylcarboxyimidamide compounds exhibiting K⁺ channel opening effects and having hypotensive action and coronary vasodilating action.

- 5 WO 00/40562 discloses novel 2-oxoquinolines as selective peripheral cannabinoid receptor modulators).

WO 97/34894 discloses Naphthyridine derivatives and their analogues inhibiting cytomegalovirus.

10

Despite the above teachings, there still exists a need in the art for novel compounds that demonstrate desirable antiviral activity.


Brief Summary of the Invention

15

In accordance with the present invention, novel compounds which demonstrate antiviral activity are provided. More specifically, the compounds are specific heterocycle carboxamide derivatives which are useful as antiviral agents, particularly against herpes viruses.

20

Even more specifically, the present invention provides a compound of formula I,



25

(I)

wherein,

X is Cl, Br, F, CN or NO₂;

G is (a) C₃₋₇alkyl which is partially unsaturated and is substituted by hydroxy, or

(b) C₁₋₇alkyl substituted by NR¹R² or 4-tetrahydropyran;


30 R¹ is C₂₋₇alkyl substituted by hydroxy, C₁₋₄alkoxy, aryl, or heteroaryl;

R² is hydrogen or C₁₋₇alkyl;

or R¹ and R² together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C₁₋₇alkyl;

W is

5



B is CR⁵ or nitrogen;

C is CR⁶ or nitrogen;

with the provisos that B and C cannot be both nitrogen;

10 R⁴ is H, halogen, or C₁₋₄alkyl optionally substituted by one to three halogens;

R⁵ is (a) H,

(b) halo;

(c) OR¹²,

(d) SR¹²,

15

(e) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,

(f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,

20

(g) (C=O)R⁹,

(h) S(O)_mR⁹,

(i) (C=O)OR²,

(j) NH₂SO₂R⁹,

(k) nitro, or

25

(l) cyano;

R⁶ is (a) H,

(b) halo,

(c) aryl,

(d) het, or

30

(e) R⁷;

R⁷ is (a) OR¹²,

(b) SR¹²,

- (c) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, aryl, halo,
C₃₋₈cycloalkyl optionally substituted by OR¹², or het attached through a carbon atom,
- 5 (d) NR¹⁰R¹¹,
- (e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
- 10 (f) (C=O)R⁹,
- (g) S(O)_mR⁹,
- (h) (C=O)OR²,
- (i) NHSO₂R⁹,
- (j) nitro, or
- 15 (k) cyano;
- R⁸ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- (c) OR¹², or
- 20 (d) SR¹²;
- R⁹ is (a) C₁₋₇alkyl,
- (b) NR¹⁰R¹¹,
- (c) aryl, or
- (d) het, wherein said het is bound through a carbon atom;
- 25 R¹⁰ and R¹¹ are independently
- (a) H,
- (b) aryl,
- (c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR²R², CO₂R², het, aryl, cyano, or halo,
- 30 (d) C₂₋₇alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR²R², OR², or SR²,

- (e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R², or
- (f) R¹⁰ and R¹¹ together with the nitrogen to which they are attached form a
 5 het;
- R¹² is (a) H,
 (b) aryl,
 (c) het
 (d) C₁₋₇alkyl optionally substituted by aryl, het, or halogen,
 10 (e) C₂₋₇alkyl substituted by OR², SR², or NR²R², or
 (f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R²;
- 15 each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR²R², CO₂R², CF₃, C₁₋₆alkoxy, and C₁₋₆
 20 alkyl which maybe further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or
 25 nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO₂R², CF₃, C₁₋₆alkoxy, oxo, oxime, and C₁₋₆ alkyl which may be further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

30 halo or halogen is F, Cl, Br, I;

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

and a pharmaceutically acceptable salt thereof.

5

In particularly preferred embodiments, X is Cl and G is 4-morpholinylmethyl.

Another embodiment of the present invention provides a pharmaceutical composition comprising a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In preferred
10 acceptable salt thereof, and a pharmaceutically acceptable carrier. In preferred embodiments, the composition preferably comprises a therapeutically effective amount of the compound or salt.

Still another embodiment of the present invention provides a method for treating a
15 disease or condition in a mammal caused by a viral infection, particularly a herpes viral infection, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. For this embodiment, in addition to the compounds encompassed by formula (I), G can also represent C₁₋₇alkyl which is fully saturated and is substituted by hydroxy.

20

A further embodiment of the present invention comprises the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating or preventing diseases or disorders caused by a viral infection, and particularly a herpes viral infection.

25

A final embodiment of the present invention comprises a method for inhibiting a viral DNA polymerase, comprising contacting (in vitro or in vivo) the polymerase with an effective inhibitory amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

30

An object of the present invention is to provide novel compounds having biological activity.

A further object of the present invention is to provide novel pharmaceutical compositions.

5 Still another object of the present invention is to provide a method for treating a disease or condition in a mammal caused by a viral infection, particularly a herpes virus infection.

Another object of the present invention is to provide a method for inhibiting a viral DNA polymerase.

10

These, and other objects, will readily be apparent to those skilled in the art as reference is made to the detailed description of the preferred embodiment.

Detailed Description of the Preferred Embodiment

15

In describing the preferred embodiment, certain terminology will be utilized for the sake of clarity. Such terminology is intended to encompass the recited embodiment, as well as all technical equivalents which operate in a similar manner for a similar purpose to achieve a similar result.

20

1. Terminology Definitions

The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl denotes both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a
25 branched chain isomer such as "isopropyl" being specifically referred to. When alkyl can be partially unsaturated, the alkyl chain may comprise one or more (e.g., 1, 2, 3, or 4) double or triple bonds in the chain.

Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at
30 least one ring is aromatic. Het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated ring containing 1, 2 or 3 heteroatoms selected from the group consisting of non-peroxide oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocyclic group. Het includes

"heteroaryl", which encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and 1, 2, 3, or 4 heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, C₁₋₄alkyl, phenyl or benzyl.

5

It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine antiviral activity using the standard tests described herein, or using other similar tests which are well known in the art.

The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating a lower and upper number of carbon atoms in the moiety, i.e., the prefix C_{i-j} indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C₁₋₇alkyl refers to alkyl of one to seven carbon atoms, inclusive.

The compounds of the present invention are generally named according to the IUPAC or CAS nomenclature system. Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" for hour or hours and "rt" for room temperature).

Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents. The compounds of the invention include compounds of formula (I) having any combination of the values, specific values, more specific values, and preferred values described herein.

Mammal denotes human and animals, specifically including food animals and companion animals.


5 2. The Invention

The present invention comprises compounds of formula (I) as defined above, and their pharmaceutically acceptable salts.

For the compounds of formula (I), alkyl can be methyl, ethyl, propyl, isopropyl, butyl,
 10 iso-butyl, sec-butyl, pentyl, 3-pentyl, hexyl, heptyl, etc.; C₃₋₈cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, hexyloxy, 1-methylhexyloxy, or heptyloxy; het can be azetidiny, 3,3-dihydroxy-1-azetiny, pyrrolidino, piperidino, morpholino, thiomorpholino, or
 15 heteroaryl; and heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide) or quinolyl (or its N-oxide).

20 When alkyl is partially unsaturated, it can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 5-hexene-1-ynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-
 25 hexynyl.

Specific examples of W include,



Particularly preferred compounds are those where X is Cl and G is 4-morpholinylmethyl.

Examples of the present invention include, but are not limited to the following:

5

N-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)-6-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(tetrahydro-2*H*-pyran-4-ylmethyl)-6-isoquinolinecarboxamide;

10

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)-6-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)-6-quinolinecarboxamide;

15 or a pharmaceutically acceptable salt thereof.


Representative examples of the synthesis of compounds falling within the scope of formula W as follows.

20 The following Charts A – D describe the preparation of the compounds of the present invention. All of the starting materials are prepared by procedures described in these charts or by procedures analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All of the final compounds of the present invention are prepared by procedures described in these charts or by procedures
25 analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All of the variables used in the charts are as defined below or as in the claims.

W2.1. 5-Hydroxy-6-isoquinolinecarboxamides. Preparation of specific examples of
30 heterocycle W2.1 follows an established literature precedent set forth in *Tetrahedron* 1973, 29, 857. and elaborated on in Charts A and B below. Benzaldehyde A.1 is condensed with 2-amino-3,3-dimethoxy-1-propanol (*Carbohydrate Res.* 1969, 10, 35-48.) to afford the corresponding imine A.2. Cyclization of A.2 by heating the imine

in a mixture of polyphoric acid (PPA) provides the isoquinoline A.3. Compound A.3 is heated in the presence of a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) to provide amides of the general formula A.4. Oxidation of the benzylic alcohol with manganese(IV)oxide or other suitable oxidizing agent affords a corresponding aldehyde of the formula A.5 which undergoes reductive amination with an amine (e.g. morpholine), acetic acid, and sodium triacetoxyborohydride to provide a compound such as A.6.

CHART A



Alternatively, to prepare compounds of structure W2.1 where G = 4-tetrahydropyranylmethyl, intermediate A.5 is protected as a methoxymethylether or other suitable phenol protecting group (Green, T. W; Wuts, P. G. M. *Protective Groups in Organic Synthesis*. Wiley, 1999) to provide B.1, Chart B. Wittig olefination between B.1 and 4-tetrahydropyranylmethylphosphonium bromide (Bestmann, H. J.; Stransky, W.; Vostrowsky, O. *Chem. Ber.* **1979**, *109*, 1694-1700.) employing sodium hexamethyldisilazide as base provides the olefin B.2. Hydrogenation of B.2 catalyzed by palladium on carbon provides B.3 by which deprotection of the phenol protecting group affords B.4. Similarly, to prepare compounds of structure W2.1 where G = 3-hydroxypropyl or 3-hydroxy-1-propynyl, intermediate B.1 is reacted with dimethoxydiazomethylphosoniumoxide in the presence of a suitable base such as potassium tert-butoxide (*Tetrahedron Lett.* **1992**, *33*, 3715) to afford the corresponding acetylene of the formula C.1, Chart C. Addition of the lithium anion of acetylene C.1 prepared

with lithium diisopropylamide or other suitable base to formaldehyde or a formaldehyde equivalent provides C.2 which following deprotection of the phenol affords derivatives of the formula C.3. Saturation of the alkyne by hydrogenation catalyzed by palladium on carbon in alcoholic solvents affords alkyl derivatives of

5 formula C.4

CHART B





CHART C




W2.2. 5-Hydroxy-6-quinolinecarboxamides. The preparation of specific examples of heterocycle W2.2. where G is 4-morpholinylmethyl is described in Chart D. Benzylic bromination of quinoline D.1 (J. M. Muchowski *J. Org. Chem.* **1991**, 56, 7288-7291.) affords alkylbromide D.2. Displacement of D.2 with morpholine provides quinoline

30 D.3. Metalation of D.3 with n-butyllithium at low temperature and trapping of the resulting anion with carbon dioxide provides carboxylic acid D.4. The resulting carboxylic acid D.4 is then coupled with a benzylamine (e.g. 4-chlorobenzylamine, 4-bromobenzylamine, or 4-fluorobenzylamine) mediated by 1,1'-carbonyldiimidazole

(or other suitable carboxylic acid activating agent) to provide amides of the general formula D.5. Deprotection of the methylether by reaction with boron tribromide provides hydroxyquinolines of the formula D.6.

5

CHART D



10

15 The inventive compounds may be used in their native form or as salts. In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, 20 etoglutarate, and glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well 25 known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

30 Compounds of the present invention can conveniently be administered in a pharmaceutical composition containing the compound in combination with a suitable excipient, the composition being useful in combating viral infections. Pharmaceutical compositions containing a compound appropriate for antiviral use are prepared by

methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E.W. Martin (Mark Publ. Co., 15th Ed., 1975). The compounds and compositions of the present invention can be administered parenterally (for
5 example, by intravenous, intraperitoneal or intramuscular injection), topically (including but not limited to surface treatment, transdermal application, and nasal application), intravaginally, orally, or rectally, depending on whether the preparation is used to treat internal or external viral infections.

10 For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be
15 between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the following:
20 binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a
25 capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or
30 fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be

incorporated into sustained-release preparations and devices such as the osmotic release type devices developed by the Alza Corporation under the OROS trademark.

5 The compounds or compositions can also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

10

Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the
15 ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be
20 maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include
25 isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

30 Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of

preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

- 5 For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
- 10 Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be
- 15 added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid
- 20 carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et

25 al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Useful dosages of the compounds of formula I can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation

30 of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

- The compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
- 10 For internal infections, the compositions can be administered orally or parenterally at dose levels, calculated as the free base, of about 0.1 to 300 mg/kg, preferably 1.0 to 30 mg/kg of mammal body weight, and can be used in man in a unit dosage form, administered one to four times daily in the amount of 1 to 1000 mg per unit dose.
- 15 For parenteral administration or for administration as drops, as for eye infections, the compounds are presented in aqueous solution in a concentration of from about 0.1 to about 10%, more preferably about 0.1 to about 7%. The solution may contain other ingredients, such as emulsifiers, antioxidants or buffers.
- 20 Generally, the concentration of the compound(s) of formula I in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.
- 25 The exact regimen for administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the individual subject being treated, the type of treatment and, of course, the judgment of the attending practitioner. The compounds of the present invention can be administered to an animal in need of treatment. In most instances, this will be a human being, but the treatment of livestock and companion animals is also specifically contemplated as
- 30 falling within the scope of the instant invention.

The compounds of formula (I) and pharmaceutically acceptable salts thereof are useful as antiviral agents. Thus, they are useful to combat viral infections in animals, including man. The compounds are generally active against herpes viruses, and are particularly useful against the varicella zoster virus, the Epstein-Barr Virus, the herpes simplex virus types 1 and 2 (HSV-1 and 2), the human herpes virus types 6, 7 and 8 (HHV-6, 7, and 8) and the human cytomegalovirus (HCMV).

The invention will be further described by the following non-limiting examples.

10

Testing of Inventive Compounds

The antiviral activity of a compound of the invention can be determined using pharmacological models which are well known to the art, or using the test described below.

While many of the compounds of the present invention can demonstrate activity against the CMV polymerase, these compounds may be active against the cytomegalovirus by this or other mechanisms of action. Thus, the description below of these compounds' activity against the CMV polymerase is not meant to limit the present invention to a specific mechanism of action.

The HCMV polymerase assay is performed using a scintillation proximity assay (SPA) as described in several references, such as N.D. Cook, et al., Pharmaceutical Manufacturing International, pages 49-53 (1992); K. Takeuchi, Laboratory Practice, September issue (1992); US Patent No. 4,568,649 (1986); which are incorporated by reference herein. Reactions are performed in 96-well plates. The assay is conducted in 100 μ l volume with 5.4 mM HEPES (pH 7.5), 11.7 mM KCl, 4.5 mM $MgCl_2$, 0.36 mg/ml BSA, and 90 nM 3H -dTTP. Assays are run with and without CHAPS, (3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane-sulfonate) at a final concentration of 2 mM. HCMV polymerase is diluted in enzyme dilution buffer containing 50% glycerol, 250 mM NaCl, 10 mM HEPES (pH 7.5), 100 μ g/ml BSA, and 0.01% sodium azide. The HCMV polymerase, which is expressed in recombinant

5 baculovirus-infected SF-9 cells and purified according to literature procedures, is added at 10% (or 10 μ l) of the final reaction volume, i.e., 100 μ l. Compounds are diluted in 50% DMSO and 10 μ l are added to each well. Control wells contain an equivalent concentration of DMSO. Unless noted otherwise, reactions are initiated via the addition of 6 nM biotinylated poly(dA)-oligo(dT) template/primer to reaction mixtures containing the enzyme, substrate, and compounds of interest. Plates are incubated in a 25 °C or 37 °C water bath and terminated via the addition of 40 μ l/reaction of 0.5 M EDTA (pH 8) per well. Reactions are terminated within the time-frame during which substrate incorporation is linear and varied depending upon the enzyme and conditions used, i.e., 30 min. for HCMV polymerase. Ten μ l of streptavidin-SPA beads (20 mg/ml in PBS/10% glycerol) are added following termination of the reaction. Plates are incubated 10 min. at 37 °C, then equilibrated to room temperature, and counted on a Packard Topcount. Linear regressions are performed and IC₅₀'s are calculated using computer software.

15

A modified version of the above HCMV polymerase assay is performed as described above, but with the following changes: Compounds are diluted in 100% DMSO until final dilution into assay buffer. In the previous assay, compounds are diluted in 50% DMSO. 4.5 mM dithiothreitol (DTT) is added to the polymerase buffer. Also, a different lot of CMV polymerase is used, which appears to be more active resulting in a more rapid polymerase reaction.

20


Having described the invention in detail and by reference to the preferred embodiments thereof, it will be apparent that modifications and variations are possible without departing from the scope of the appended claims.

25

WHAT IS CLAIMED IS:

1. A compound of formula I,

5



(I)

wherein,

X is Cl, Br, F, CN or NO₂;

10 G is (a) C₃₋₇alkyl which is partially unsaturated and is substituted by hydroxy, or

(b) C₁₋₇alkyl substituted by NR¹R² or 4-tetrahydropyran;

R¹ is C₂₋₇alkyl substituted by hydroxy, C₁₋₄alkoxy, aryl, or heteroaryl;


R² is hydrogen or C₁₋₇alkyl;

or R¹ and R² together with the nitrogen to which they are attached form morpholine

15 which may be optionally substituted by aryl or C₁₋₇alkyl;

W is

20



B is CR⁵ or nitrogen;

C is CR⁶ or nitrogen;

with the provisos that B and C cannot be both nitrogen;

25 R⁴ is H, halogen, or C₁₋₄alkyl optionally substituted by one to three halogens;

R⁵ is (a) H,

(b) halo,

(c) OR¹²,

(d) SR¹²,

30 (e) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,

- (f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
- (g) (C=O)R⁹,
- 5 (h) S(O)_mR⁹,
- (i) (C=O)OR²,
- (j) NHSO₂R⁹,
- (k) nitro, or
- (l) cyano;
- 10 R⁶ is (a) H,
- (b) halo,
- (c) aryl,
- (f) het, or
- (g) R⁷;
- 15 R⁷ is (a) OR¹²,
- (b) SR¹²,
- (d) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, aryl, halo,
- 20 C₃₋₈cycloalkyl optionally substituted by OR¹², or het attached through a carbon atom,
- (d) NR¹⁰R¹¹,
- (e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹²,
- 25 SR¹², or NR¹⁰R¹¹,
- (f) (C=O)R⁹,
- (g) S(O)_mR⁹,
- (h) (C=O)OR²,
- (i) NHSO₂R⁹,
- 30 (j) nitro, or
- (k) cyano;
- R⁸ is (a) H,

- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- (c) OR¹², or
- (d) SR¹²;
- 5 R⁹ is (a) C₁₋₇alkyl,
- (b) NR¹⁰R¹¹,
- (c) aryl, or
- (d) het, wherein said het is bound through a carbon atom;
- R¹⁰ and R¹¹ are independently
- 10 (a) H,
- (b) aryl,
- (c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR²R², CO₂R², het, aryl, cyano, or halo,
- 15 (d) C₂₋₇alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR²R², OR², or SR²,
- (e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R², or
- 20 (f) R¹⁰ and R¹¹ together with the nitrogen to which they are attached form a het;
- R¹² is (a) H,
- (b) aryl,
- (c) het
- 25 (d) C₁₋₇alkyl optionally substituted by aryl, het, or halogen,
- (e) C₂₋₇alkyl substituted by OR², SR², or NR²R², or
- (f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R²;
- 30 each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR^2R^2 , CO_2R^2 , CF_3 , C_{1-6} alkoxy, and C_{1-6} alkyl which maybe further substituted by one to three SR^2 , NR^2R^2 , OR^2 , or CO_2R^2 groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO_2R^2 , CF_3 , C_{1-6} alkoxy, oxo, oxime, and C_{1-6} alkyl which may be further substituted by one to three SR^2 , NR^2R^2 , OR^2 , or CO_2R^2 groups;

halo or halogen is F, Cl, Br, I;

15

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

20

and a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein W is of the formula W2.1.

25 3. A compound of claim 1 wherein W is of the formula W2.2.

4. The compound according to claim 1, wherein X is Cl.

5. The compound according to claim 1 wherein G is 4-morpholinylmethyl.

30

6. The compound according to claim 1 wherein G is 3-hydroxy-1-propynyl.

7. The compound according to claim 1 wherein G is tetrahydro-2*H*-pyran-4-ylmethyl.
8. The compound according to claim 1 which is
- 5 *N*-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)-6-isoquinolinecarboxamide;
- N*-(4-chlorobenzyl)-5-hydroxy-3-(tetrahydro-2*H*-pyran-4-ylmethyl)-6-isoquinoline-carboxamide;
- 10 *N*-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)-6-isoquinolinecarboxamide;
- N*-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)-6-quinolinecarboxamide;
- or a pharmaceutically acceptable salt thereof.
- 15
9. A pharmaceutical composition comprising a compound of claims 1 to 8 and a pharmaceutically acceptable carrier.
10. A use of compound of claims 1 to 8 to prepare a medicament for treating or
- 20 preventing a viral infection in a mammal.
11. A use according to claim 10 wherein said viral infection is a herpes virus infection.
- 25 12. A use according to claim 10 wherein said mammal is a human.
13. A use according to claim 10 wherein said mammal is a food animal or companion animal.
- 30 14. A use according to claim 10 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type, 6, 7, or 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

15. A use according to claim 10 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.
- 5 16. A use according to claim 10 wherein the amount administered is from about 0.1 to about 300 mg/kg of body weight.
17. A use according to claim 10 wherein the amount administered is from about 1 to about 30 mg/kg of body weight.
- 10 18. A use according to claim 10 wherein the compound is administered parenterally, topically, intravaginally, orally, or rectally.
19. A use for inhibiting a viral DNA polymerase, comprising contacting the
15 polymerase with an effective inhibitory amount of a compound of the formula (I).
20. A use of claim 19 wherein the polymerase and the compound are contacted *in vitro*.
- 20 21. A use of claim 19 wherein the polymerase and the compound are contacted *in vivo*.